Many or all of the products on this page are from partners who compensate us when you click to or take an action on their website, but this does not influence our evaluations or ratings. Our ...
The documents posted on this site are XML renditions of published Federal Register documents. Each document posted on the site includes a link to the corresponding official PDF file on govinfo.gov.
STUTTGART, Germany — The prospective next Pentagon chief says he will prioritize a military buildup in the Pacific in connection with a global force review that will reassess how many troops are ...
Sunvozertinib received FDA priority review for NSCLC with EGFR exon 20 insertion mutations ... While sunvozertinib is being studied as a second line or later treatment in the WU-KONG 1 Part B trial, ...
The FDA has accepted and granted priority review to the BLA for Dato-DXd for adult patients with locally advanced or metastatic EGFR-mutated NSCLC who have previously received systemic therapies, ...
Application based on TROPION-Lung05 phase 2 trial and supported by data from TROPION-Lung01 phase 3 and TROPION-PanTumor01 phase 1 trials Daiichi ... and granted Priority Review in the U.S ...
Application based on TROPION-Lung05 phase 2 trial and supported by data from TROPION-Lung01 phase 3 and TROPION-PanTumor01 phase 1 trials TOKYO & BASKING RIDGE ... has been accepted and granted ...
The document viewed by BI showed a new field focusing on employee contributions in artificial intelligence. "In the context of AI transformation as a key priority ... Signal (+1-425-344-8242 ...
Priority review was granted by the FDA for sunvozertinib (DZD9008), an oral EGFR inhibitor, to treat patients with platinum-pretreated, locally advanced, or metastatic NSCLC with EGFR exon 20 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback